Alefacept: A novel and selective biologic agent for the treatment of chronic plaque psoriasis

European Journal of Dermatology

Volumn 14, Issue 1, 2004, Pages 41-45

  Ortonne, Jean Paul ^a   Prinz, Jörg C ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alefacept; Amevive ; Efficacy; Psoriasis; Quality of life

Indexed keywords

ALEFACEPT; COLECALCIFEROL DERIVATIVE; HYBRID PROTEIN; METHOXSALEN; RECOMBINANT PROTEIN;

ARTICLE; BALNEOTHERAPY; CHRONIC DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; LYMPHOCYTE PROLIFERATION; MEMORY CELL; PATHOGENESIS; PHOTOTHERAPY; PSORIASIS VULGARIS; PUVA; QUALITY OF LIFE; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL THERAPY; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT FUSION PROTEINS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0442329149     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Barker JN. Psoriasis as a T cell-mediated autoimmune disease. Hosp Med 1998; 59: 530-3.
2. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002; 46: 850-60.
3. Piercy J, Mesrobian X, Viala M, Evans C, Prosek B. Estimating the cost of moderate to severe chronic plaque psoriasis in the UK. JEAV 2002; 16: 284. [Abstract P27-32].
4. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Arch Dermatol 2001; 137: 280-4.
5. Wong C, Kirby B. Managing the patient with psoriasis. Practitioner 2001; 245: 913-22.
6. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
7. Faber FM, Nall L. Psoriasis and alcoholism. Cutis 1994; 53: 21-7.
8. Messana JM, Johnson KJ, Mihatsch MJ. Renol structure and function effects after low dose cyclosporine in psoriasis patients: a preliminary report. Clin Nephrol 1995; 43: 150-3.
9. Zachoriae H, Kragballe K, Hansen HE, Morcussen N, Olsen S. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 1997; 36: 531-5.
10. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41: 51-9.
11. Lindelöf B, Sigurgeirsson B, Tegner E, Larkö O, Johannesson A, Berne B, Ljunggren B, Andersson T, Molin L, Nylander-Lundqvist E, Emtestam L. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141: 108-12.
12. Shephard SE, Panizzon RG. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy. Dermatology 1999; 199: 106-12.
13. Stern RS, the PUVA Follow-up Study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-61.
14. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Safety 2002; 25: 913-27.
15. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN, for the Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and safety of 2 courses of alefacept in patients with chromic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-33.
16. Lebwohl M, Christophers E, Langley R, Ortonne J-P, Roberts J, Griffiths CEM, for the Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719-27.
17. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis. The new therapeutic frontier. Arch Dermatol 2002; 138: 657-63.
18. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner BP. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993; 178: 211-22.
19. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994; 152: 2753-67.
20. Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA, Shaw S. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-g production. J Immunol 1988; 140: 1401-07.
21. + T cells is independent of cell activation. Cell Adhes Commun 1999; 7: 267-79.
22. Ellis CN, Krueger GG, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-55.
23. Ortonne J-P, Prinz JC, Bos JD, Wozel G, Lahfa M, Dubertret L, O'Gorman J. Efficacy and tolerability of retreatment with intramuscular alefacept in psoriasis patients. JEAV 2002; 16: 283. [Abstract P27-30].
24. Finlay AY, Salek MS, Haney J, for the Alefacept Clinical Study Group. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206: 307-15.
25. Feldmon SR, Menter A, Koo JY. Improved health-related quality of life following alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol in press.